Medicine levy makes the UK un-investable, say pharma leaders
Leaders from across a key growth sector for the government’s upcoming industrial strategy say future UK investment is unlikely unless an unsustainable levy on manufacturers is addressed.
Read the full articleYou might also wanna read
Starmer's US pharma deal criticized as costly threat to NHS and public health
The deal on medicine imports will cost the NHS billions and take funding away from doctors, nurses, cancer scans and the rest, says Guardian
theguardian.com·8d agoStarmer's US pharma deal criticized as costly, harmful to NHS, and a democratic failure
The deal on medicine imports will cost the NHS billions and take funding away from doctors, nurses, cancer scans and the rest, says Guardian
theguardian.com·8d ago
India’s Generic Pharma Industry Is Sitting on a Formulation Data Time Bomb
Discover how fragmented formulation data is slowing India's generic pharma industry and why AI-powered knowledge systems are becoming essent
Starmer's US pharma deal criticized as costly threat to NHS funding and public health
The deal on medicine imports will cost the NHS billions and take funding away from doctors, nurses, cancer scans and the rest, says Guardian
theguardian.com·8d agoTrump’s drug price crusade puts Europe on guard
UK has given in to pharma industry lobbying but some EU member states promise to stand firm
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across
Comments
Sign in to join the conversation.
No comments yet. Be the first.